Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Bullboard Posts
Post by jpinkmanon Oct 10, 2018 11:26am
223 Views
Post# 28773180

Georges letter!

Georges letter!or dream, er whatever it was in early june. maybe a rehash will make everyones feel ... there is a dire need and market for this?

Dear Friend;
 
Attached is news we released today.  her is some background.
 
1. Cancer is a big application with 23M people in USA with cancer and 1.7M new patients a year.  Since all chemotherapy agents hurt the heart, the American Heart Association (AHA) has put out a statement saying cancer patients should ask to have their heart examined before, during and after therapy as they are more likely to die from heart problems than cancer after they have the therapy.
2. MD Anderson has been ranked as the number one cancer hospital in the USA 28 out of the last 30 years and is clearly the leader in clinical innovation, so we are very pleased they have ordered the VMS+ and will immediately start using it clinically - no research study as they know heart problems are prevalent.
3. MD Anderson is not just a hopsital but a network of several hospitals who see 1.5M patients per year and perform almost 600,000 imaging studies. This network would need 750 VMS+ devices to treat their patients according to the AHA guidelines (3 scans per patient) at full utilization.  Many survey’s have shown ultrasound equipment is used only 50% to 60% of the capacity due to scheduling and other issues, so in reality they would need 1,500 machines just for their network.  The chief cardiologists will be using the VMS+ initially in the main hospital in Houston to get a good understanding of how it works and how it can be used in all their hospitals.
4. There are 1,500 cancer centres in USA, who deal with the 23M patients.  Patients come back twice a year to check to see if the cancer has regrown and the AHA is saying they really should be more worried about heart conditions then cancer.  Ask anyone you know who has cancer therapy of they have had an echocardiogram.  I am doing this and I have yet to find anyone.  To follow the AHA guidelines in the USA with the normal utilization rates would require 20,000 VMS+ machines.  At $75,000 each this would be  $1.5B of sales.  That is just the USA.  European market is 1.5 times the USA.
5. Note hypertension (100 million people in USA , 80,000 VMS+ machines needed) is an even bigger application and we are working on a lead order in this space as well.
6. Reducing the use of contrast media which is used in 20-30% or all echocardiograms (40M per year in USA) is another large application which would require 3,000 VMS+ machine to address.
 
Thank you for your continued support,
 
George Adams
 
Bullboard Posts